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Summary Twenty-six patients with relapsed or drug-resistant cancer were treated with a combination of oral
etoposide (300 mg day-' for 3 days) and high-dose oral tamoxifen as a potential modulator of drug resistance
(480 or 720mgday-' for 6 days beginning 3 days before etoposide). One patient with relapsed high-grade
lymphoma and one with adenocarcinoma of unknown primary site has a partial response. Toxicity consisting
of nausea, vomiting and subjective dizziness, unsteadiness of gait and malaise occurred during tamoxifen
treatment. Serum levels of tamoxifen averaged 3-3.5 gM on day 4 of all courses of treatment at both 480 and
720 mg day-'. N-desmethyltamoxifen levels were lower than tamoxifen during the first course (2 JM) but
increased to equal tamoxifen levels during the second course. Didesmethyltamoxifen levels remained below
1 gM. In vitro, both tamoxifen and the standard modulator ofmultidrug resistance, verapamil, produced minor
enhancement ofetoposide cytotoxicity in the MCF-7 wt cell line but produced no enhancement with any other
cell line. High, intermittent doses of tamoxifen can be given with acceptable toxicity and produce serum levels
that have been shown to modulate drug resistance in vitro. In vitro, however, such levels have no significant
effect on etoposide cytotoxicity towards a range of wild-type and MDR cell lines.
Cytotoxic drug resistance frequently affects a wide range of
cytotoxic agents. It is commonly inherent, although it may
also be acquired after initial response to cytotoxic drugs. Cell
lines exposed in vitro to one cytotoxic drug may also become
resistant to a range of structurally and functionally diverse
agents. This multidrug resistant (MDR) phenotype is associ-
ated with the presence of a 170 kd membrane glycoprotein,
the P-glycoprotein (Pgp) (Juliano et al., 1976; Kartner et al.,
1983; Riordan et al., 1985) which acts as an energy depen-
dent efflux pump (Skovsgaard, 1978). Many compounds have
been shown to inhibit the action of Pgp thereby partly or
completely overcoming drug resistance. Such resistance modi-
fiers include verapamil (Tsuruo et al., 1981) and other cal-
cium antagonists, phenothiazines (Ford et al., 1989) and
cyclosporin A (Nooter et al., 1989).
Many studies have attempted to reproduce the resistance
modifying action of these drugs in a clinical setting. Unfor-
tunately many cause unacceptable toxicity at levels below
those needed to modulate resistance and have therefore not
been useful clinically (Ozols et al., 1987). Some encouraging
results have however been reported in lymphoid malignan-
cies. Verapamil and cyclosporin A appear to be able to
reverse clinical drug resistance in myeloma and acute myelo-
cytic leukaemia respectively (Dalton et al., 1989; Nooter et
al., 1989).
The anti-oestrogen tamoxifen is one of the compounds that
can modify multidrug resistance (Chatterjee et al., 1990b). It
is widely used in the treatment of breast cancer at doses of
20-40mgday-' and at such doses produces serum levels
around 0.5 JiM (Adam et al., 1980; Fabian et al., 1980; Lien
et al., 1989). Doses up to 100mgday-' have however been
used with little toxicity, except for retinal toxicity after con-
tinuous treatment for periods of longer than 12 months
(Kaiser-Kupfer et al., 1978). High doses of tamoxifen may
thus have the potential to produce serum levels sufficient to
modulate multidrug resistance in vitro (3-10JAM) (Chatterjee
et al., 1990b; Foster et al., 1988; Ramu et al., 1984) making it
an interesting compound to assess as a modifier of clinical
drug resistance.
Etoposide (VP16-213, Vepesid) is an epipodophyllotoxin
derived cytotoxic drug which interferes with the action of the
nuclear enzyme topoisomerase II producing lethal single and
double stranded DNA breaks (Chen et al., 1984). It has
activity in a number of solid tumours and resistance to it is
part of the typical MDR phenotype (Endicott et al., 1989).
Etoposide is active orally and has manageable toxicity mak-
ing it an attractive agent to combine with tamoxifen to
produce an out-patient regimen.
We have therefore untaken a clinical study of oral etopo-
side in combination with intermittent, high-dose tamoxifen.
This study has the dual aims of determining the maximum
serum levels of tamoxifen and its metabolites that could be
achieved and of assessing the toxicity and feasibility of the
drug combination. The study therefore included patients with
a range of relapsed and chemoresistant tumours. In conjunc-
tion with this we have assessed the in vitro effects of tamox-
ifen on etoposide cytotoxicity towards a panel of MDR + ve
and MDR -ve cell lines and have compared this to the
effects of the known MDR modulator verapamil.
Materials and methods
Patient group
Patients selected had histologically proven malignancy which
had relapsed after or was resistant to standard therapy.
Patients had ECOG performance scores of 2 or better, had
normal renal and hepatic function and had normal peripheral
blood counts. No patient had received systemic therapy in
the 4 weeks prior to starting study treatment. The treatment
protocol was approved by the local ethical committee and all
patients gave informed consent prior to starting treatment.
Studyprotocol
Treatment comprised high-dose oral tamoxifen combined
with oral etoposide. Tamoxifen was given on days 1 to 6,
etoposide on days 4 to 6 and treatment was repeated each 3
weeks. We have previously used tamoxifen at a dose of
320 mgday-' for 6 days (Millward et al., 1992) and in this
study the first nine patients received 480 mgday-'. As no
dose-limiting toxicity was noted the subsequent 16 patients
received 720mg day-' (12 20mg tablets, three times day-').
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No formal compliance check was conducted but patients
were asked specifically whether they had difficulties taking
the correct number of tablets. Oral etoposide was given at a
dose of 300mgday-' (150mg two times day-') for the first
course. Patients who remained myelosuppressed on day 21
had the dose ofetoposide reduced to 200 mg day-' for subse-
quent courses. In those who had no significant myelosuppres-
sion the dose of etoposide was increased to 400 mg day-'.
Blood was taken for assessment of serum levels of tamoxifen
and its metabolites on the morning of the fourth day of
treatment between 1 and 4 h after the last dose and
immediately prior to starting etoposide. A blood sample was
also drawn on day 21 of the first course of treatment, i.e.
after 15 days without tamoxifen and immediately before
starting course 2. Blood samples were centrifuged and the
serum removed and stored at -20°C prior to measurement.
Determination oflevels oftamoxifen and its metabolites
Levels of tamoxifen and its metabolites were measured using
high-performance liquid chromatography. The methods used
have been published previously (Lien et al., 1989; 1987).
Briefly, tamoxifen and its metabolites were determined in the
acetonitrile extract from serum and were separated by
reverse-phase, low-dispersion, liquid chromatography. The
drugs were detected by being converted to fluorophors by
subjecting the effluent of the column to ultra-violet light
while passing through a quartz tube. The identity of the
analyses was confirmed by liquid chromatography/mass spec-
trometry using an on-line mass spectrometer connected to the
analytical column (Lien et al., 1988). Serum levels in different
patient populations were compared using the Mann-Whitney
U-test.
Cells and culture conditions
Three pairs of cell lines were assessed. Each comprised a
wild-type parental cell line and a P-glycoprotein expressing
daughter line. The wild-type MCF-7 cell line was derived
from a human breast cancer (Soule et al., 1973) while the
CHO-KI cell line was derived from Chinese hamster ovaries
(CHO). The doxorubicin hydrochloride (dox)-resistant daugh-
ter lines of each (MCF-7 adrr and CHO-KI adrr respectively)
were developed by stepwise exposure to increasing dox con-
centrations (Batist et al., 1986; Chatterjee et al., 1990a). Both
express Pgp and have a typical MDR phenotype. The SI cell
line (also known as SW-1573) was isolated from a human
squamous cell lung cancer by Dr Leibovitz (Scott and White
Clinic, Temple, TX). Its resistant offspring (S1/1.1) was pro-
duced by F. Baas (Neurozintuigenlab K2-214, 1105 AZ
Amsterdam) by transfecting the Sl cell line with an expres-
sion vector (PFRCMV mdrl) bearing a full-length cDNA of
the human mdrl gene isolated from human liver using prev-
iously described methods (Lincke et al., 1990). mdrl expres-
sion in the S1/1.1 cell line is at least 100 fold higher than in
the S1 line (F. Baas, personal communication) while mdrl
mRNA levels are about 5-fold higher than in the highly
resistant 1R500 cell line produced from SWi573 by stepwise
exposure to dox (Baas et al., 1990).
Cell lines were grown at 37°C under 5% CO2 in either
RPMI 1640 (human cells) or Ham's F12 (CHO cells)
medium, each supplemented with 10% foetal bovine serum
and 2 mM glutamine. All cell lines were regularly sub-
cultured to maintain them in exponential growth phase and
were regularly tested to ensure they were free of mycoplasma
infection.
Drugs
Etoposide (vepesid, VP16-213) formulated for intravenous,
clinical use (Bristol-Myers Oncology, Slough, UK) was used
in all experiments. Stock solutions as supplied by the
manufacturers (20mgml-', 34mM) was diluted in PBS to
final concentration. Tamoxifen (supplied by ICI Pharmaceu-
ticals PLC, Macclesfield, UK) and verapamil (Sigma Chemi-
cals, Poole) were prepared as stock solutions at 50 mM in
absolute ethanol and were stored at 4°C. Dilution to final
concentration were made in PBS.
Drug sensitivity assay
The semi-automated, colorimetric, MTT assay was used to
assess drug sensitivity (Carmichael et al., 1987). Cells in
exponential growth-phase were harvested by trypsinisation
and seeded into 96-well plates in 180il fresh medium. The
number of cells seeded varied from 2,000 to 8,000, according
to the cell line, and was such that the control well was
non-confluent at the end of the 4 day experiment. Drugs were
added in a volume of 10 il (PBS alone in control wells) to
give a final volume of 200 ltl. Cells were incubated for 4 days
at 37°C under 5% CO2. MTT was then added (50IL of
2 mgml1' = 0.1 mg), the cells incubated for a further 4 h and
the medium removed by inverting the plate. The formazan
crystals were then dissolved in 100ytL DMSO plus 25 IlI
glycine buffer pH 10.5 (Plumb et al., 1989). Optical density at
540 nm was read on a Titertek Multiscan ELISA plate
reader. Data was transferred to a Macintosh microcomputer
and analysed using DeltaSoft software (BioMetallics Inc)
which calculated IC50 values. ICm was defined as the concen-
tration of drug which reduced optical density to 50% of the
control (non-drug) value.
The effect of tamoxifen on etoposide cytotoxicity was
assessed at 1.5, 7.5 and 15 giM, the effect of verapamil was
assessed at 6.6JLM. Maximum non-toxic concentration
(MNTC) of tamoxifen was defined as the highest level that
showed less than 10% growth inhibition when used alone.
The extent of modulation of drug sensitivity was calculated
by dividing the IC50 for etoposide alone by that for etoposide
in the presence of modifer. Enhancement values above 1.0
indicate enhancement of cytotoxicity while values below 1.0
indicate inhibition. Experiments were repeated at least three
times and the values obtained under different conditions
compared using the paired t-test.
Results
Clinical results
Twenty-six patients were studied and their characteristics are
listed in Table I. Median age was 50, median performance
score 1. A range of histological tumour types were included
with the dominant types being renal cell carcinoma (n = 6),
gastrointestinal adenocarcinoma (n = 4), adenocarcinoma of
unknown primary site (n = 4) and breast carcinoma (n = 3).
Nine patients had received previous chemotherapy.
Response Two patients showed a partial response. One had
intermediate grade lymphoma which had previously respond-
ed to combination chemotherapy including dox, cyclophos-
phamide and vincristine while the other had previously
untreated adenocarcinoma of unknown primary site. Three
patients had static disease for 24, 28 and 39 weeks, 16
patients showed no response and five patients died within
two courses of treatment.
Toxicity The toxicity of the regimen is summarised in Table
II. Nausea or vomiting occurred in four of 27 (15%) courses
assessed at 480mg day-' tamoxifen and in 10 of 30 (33%)
courses assessed at 720 mg day'-. Significant nausea was
most commonly associated with the tamoxifen treatment and
generally commenced before the etoposide therapy. A
number of patients experienced subjective neurological symp-
toms. These were ill defined and were described as 'dizziness',
unsteadiness of gait or marked malaise. These symptoms did
not match standard WHO toxicity categories and were grad-
ed as mild (minimal symptoms), moderate (significant symp-
toms not requiring action), severe (significant symptoms
requiring intervention) or very severe (unable to continue
treatment). No objective neurological signs were noted. TheseTAMOXIFEN AS ENHANCER OF ETOPOSIDE CYTOTOXICITY 835
Table I Characteristics of patients included in clinical study
Number ofpatients entered on study
Male: Female
Median age (range)
Median ECOG score at start of treatment
Histological type
Renal cell adenocarcinoma
Gastrointestinal adenocarcinoma
Adenocarcinoma of unknown primary site
Breast carcinoma
Soft tissue sarcoma
Bronchial carcinoma
Cervical carcinoma
Bladder, tonsil (squamous), high-grade
lymphoma
Tamoxifen dose received with first course
26
12:14
50 (36-77)
1 (0-2)
6
4
4
3
2
2
2
1 each
al60mg= 1
480 mg = 9
720 mg = 16
Number with prior chemotherapy
0
0
0
3
2
1
2
a160 mgday-' tamoxifen given to one patient with brain metastases.
Table II Toxicity of treatment
Frequency (number ofcourses) and severity ofnausea and vomiting
Tamoxifen dose Grade 0 Grade 1/2 Grade 3/4 Not known Total
480 mgday-' 23 3 1 3 30
720 mgday-' 20 6 4 5 35
Number ofpatients experiencing neurological symptoms andgrade
Tamoxifen dose None Mild/moderate Severe/v. severe Total
480mgday-' 7 3 (30%) 0 10
720mgday-' 11 4 (25%) 1 (6%) 16
symptoms occurred in three of ten patients while receiving
480mgday-' tamoxifen and in five of 16 while receiving
720 mg day-1. Seven hundred and twenty mg day-' was
considered the maximum tolerated dose of tamoxifen given
by this schedule.
Twelve of 35 cycles of treatment at 300 mg day' ofetopo-
side were associated with leucopenia (WHO grade three or
four in four courses). No significant thrombocytopenia was
recorded. Six patients had their etoposide dose reduced from
300 to 200mgday-' because of myelosuppression while in
three the dose was increased from 300 to 400 mg day-'. No
patients had to stop treatment because of toxicity.
Pharmacokinetics
The level of tamoxifen and two of its metabolites on the
morning of day 4 of the first three courses of treatment at
6
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480 and 720 mgday-' are shown in Figure 1. Tamoxifen
levels averaged 3.5 LM after the first 3 days of treatment at
480 mgday-' and 3.2ftM after 3 days of treatment at 720 mg
day-I (not significantly different). Levels of N-desmethyl-
tamoxifen were lower than those of tamoxifen (2.1 gM and
2.2liM after the first 3 days of treatment at 480 and 720 mg
day-' respectively), while didesmethyltamoxifen were about
5-10% of tamoxifen levels during the first course (0.15 1M
and 0.14ILM after 480 and 720mgday-' respectively). After
completing 6 days treatment with 720 mgday-' levels of
tamoxifen fell to below 1 JLM by day 21 but N-desmethyl-
tamoxifen levels remained static (2.1 tLM on day 21) while
didesmethyltamoxifen levels rose, reaching 0.5 liM.
Levels of tamoxifen and its metabolites on day 3 of the
first three courses were not significantly different in patients
receiving 720 mg day-' compared to those receiving 480 mg
day-'. Similarly levels of tamoxifen on day 3 of course 1
720 mg day- 1
t
*~~~
1 [n = 101 2 [n= 71 3 [n = 61
Course number [number of patients assessedl
Figure 1 Serum levels (gLM±s.e. where n>2) of tamoxifen (0), N-desmethyltamoxifen (*) and didesmethyltamoxifen (A) on the
fourth day of the first three 6 day courses at two tamoxifen dose levels. *,t =levels significantly different, P<0.01.
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were not statistically different to those on day 3 of subse-
quent courses. N-desmethyltamoxifen levels were however,
higher in course 2 than in course 1. Similar levels were
achieved after 480 mg day'1 (2.1 JiM during course 1 vs
3.2 JAM during course 2) to those after 720 mg day-' (2.2 JLM
vs 3.36 LM) but only in the latter case was this difference
significant (P<0.01). Didesmethyltamoxifen levels were also
significantly higher during course 2 that during course 1 after
both 480mgday-' (0.1i5IM rising to 0.45IsM, P<0.001)
and 720mgday-' (0.141AM rising to 0.48tM, P<0.01).
Didesmethyltamoxifen levels however, remained below
1.0 iM.
In vitro effects
Table III and IV show the effects of tamoxifen and verapamil
respectively, on the cytotoxicity of etoposide towards the cell
lines used. In comparison to the MCF-7 wild type cell line
the MCF-7 adrr cell line showed 60-fold resistance to etopo-
side while the CHO-Ki adrr line was 5-fold more resistant
than its parental line. The SI/i .1 cell line, which has been
transfected with the mdrl gene, was however 2-fold more
sensitive than the parental line (P<0.01). Tamoxifen pro-
duced a minor degree of enhancement of etoposide cytotox-
icity in the MCF-7 parental cell line reducing the IC50 from
0.9511M to 0.77 gM (P<0.01) but had the opposite effect in
the MCF-7 adrr line where IC50 increased from 60JM to
84 JLM (P<0.005). Tamoxifen had no significant effect on the
cytotoxicity of etoposide towards the SI, Si/l.1, CHO-KI or
CHO-KI adrr cell lines. Verapamil at 6.6JAM had a similar
effect to tamoxifen on the cell lines producing enhancement
of etoposide cytotoxicity in the MCF-7 wt cell line
(P<0.03), minor inhibition in the MCF-7 adrr cell line and
no significant effect on the CHO-KI and SI cell lines.
Discussion
We report here both clinical and in vitro studies of the effects
of tamoxifen on etoposide cytotoxicity and also the serum
levels of tamoxifen and its metabolites that can be achieved
with intermittent high-dose tamoxifen. The clinical study
assessed a range of solid tumours and showed two responses
among 26 patients (in relapsed lymphoma and in untreated
adenocarcinoma). As this was a phase I study designed to
assess the feasibility of administering the combination of
drugs it is not possible to determine the contribution of the
tamoxifen to these responses as both tumour types can res-
pond to etoposide alone. Treatment toxicity was generally
manageable and was less marked than that reported with
480 mg day-' continuously (Stuart et al., 1991). Nevertheless,
we consider that 720 mg day-' is the maximum tolerated
dose for tamoxifen given by this schedule. Thirty-three per-
cent of courses at 720 mg day-' were associated with nausea
or vomiting although no patient stopped treatment because
of this. Neurological toxicity occurred in a number of
patients taking both 480 and 720 mg day-' and comprised
the same subjective symptoms noted by us in patients taking
480mg day-' continuously (Stuart et al., 1991) as well as by
others (Trump et al., 1991). The mechanism of such toxicity
is not known but Lien et al. have recently reported levels of
tamoxifen in brain metastases and in normal brain tissue in
four patients taking standard dose tamoxifen (Lien et al.,
1991). They showed that brain levels are some 46-fold higher
than serum levels. Although the distribution of tamoxifen at
high doses may be different from the standard doses assessed
by Lien et al., it is likely that brain levels are considerably
higher than the serum levels reported in the present study. It
is also possible that tamoxifen alters the tissue distribution of
etoposide rendering it more neurotoxic. The possibility that
resistance modifiers may exacerbate the normal tissue toxicity
of chemotherapy has been raised by one non-randomised
study (Berd et al., 1991). The extent of myelosuppression
observed in this study was similar to that expected.
Several studies have described the pharmacokinetics of
standard dose tamoxifen (20-40 mg day-') and the levels of
its metabolites that result (Adam et al., 1980; Fabian et al.,
1980; Lien et al., 1989). These studies show steady state
serum levels of tamoxifen of around 0.25-1.0IJM after 4
weeks. NDMTx accumulated more slowly to levels some
50% higher after 8 weeks. diDMTx levels are generally about
60-85% lower than those of the parent compound. These
ratios are similar to those in the present study but the levels
produced by high-dose therapy are lower than expected,
indicating non-linear pharmacokinetics. The fact that serum
levels were not significantly higher after 720 mgday-' than
Table III Cytotoxicity of etoposide and tamoxifen towards each cell line (IC50), maximum
non-toxic concentration of tamoxifen (MNTC), IC,,, in the presence of MNTC, degree and
significance ofenhancement
IC50 IC50 MNTC IC50 etoposide at
etoposide tamoxifen tamoxifen MNTC tamoxifen
Cell line (pM±s.e) ("AM) (PM) (gM±s.e.) Enhancement P-value
MCF-7 wt 0.95±0.12 8.3 0.15 0.77±0.09 1.2 P<0.01
MCF-7 adri 60±6 20 7.5 89.±7 0.7 P<0.005
CHO-Ki 1.2±0.45 10 1.5 1.2±0.46 1.0 n.s.
CHO-KI adrr 5.2±1.68 7.8 1.5 6.1±1.63 0.85 n.s.
Si 2.8±0.51 12 7.5 3.1±0.97 0.9 n.s.
Sl/1.1 1.7±0.39 12 7.5 1.96±0.56 0.9 n.s.
Values represent mean value of at least three experiments.
Table IV Cytotoxicity ofetoposide towards eachcell lines(ICu), IC50 in the presence
of 6.6#AM verapamil and degree and significance of enhancement
IC50 IC50 etoposide at
etoposide 6.6JAM verapamil
Cell line (ILM±s.e.) (gm M±s.e.) EnhancementP-value
MCF-7 wt 1.02±0.21 0.54±0.11 1.9 <0.03
MCF-7adr' 66±6 91±11 0.73 n.s.
CHO-KI 1.2±0.57 0.76±0.36 1.6 n.s.
CHO-KI adrr 5.6± 1.97 4.4±4.38 1.3 n.s.
Si 3.6±0.79 3.0±0.76 1.2 n.s.
Sl/1.1 1.5±0.32 1.6±0.37 0.9 n.s.
Values represent mean value ofat least three experiments.TAMOXIFEN AS ENHANCER OF ETOPOSIDE CYTOTOXICITY 837
after 480 mg day-' supports this. Non-linear pharmacokine-
tics may be due to lower bioavailability of high oral doses or
to saturation of portal vein plasma proteins leading to in-
creased hepatic, pre-systemic metabolism. However, patients
on the higher dose were asked to take 36 tablets each day
and it is possible that compliance was incomplete. We cannot
exclude the possibility that the apparent non-linear pharma-
cokinetics were due, in part, to failure of patients to take the
full dose. Tamoxifen also has a very high volume of distribu-
tion (Lien et al., 1989) and higher doses may have produced
increased drug influx into the tissues. Blood sampling took
place 1 to 4 h after treatment but did not necessarily coincide
with peak levels. The influx into tissues may have been
promoted by peak serum levels higher than those recorded.
The greater toxicity of higher doses suggests that they pro-
duce higher levels in some tissues even though serum levels
were similar.
The slower fall in levels of NDMTx and diDMTx while
not taking tamoxifen, and the accumulation with subsequent
courses is consistent with previous reports of the longer
half-life of these compounds (Adam, 1981; Lien et al., 1987).
The finding of non-linear pharmacokinetics is of clinical
relevance in that it limits the ability to achieve high serum
levels. A dose of 720 mg day-' for 3 days produces levels no
higher than 480 mg day-' (about 3 JAM) while continuing
480 mg day-' indefinitely raises levels only marginally to
around 4gM (Stuart et al., 1991). Trump et al. have reported
somewhat higher serum levels of both tamoxifen (6.1 gM)
and NDMTx (6.6 JAM) after 9 days on 260 mg of tamoxifen
twice a day (Trump et al., 1991). Full pharmacokinetics were
though, not reported, so it is difficult to relate these findings
to the present study. Trump et al. used more prolonged
treatment and reported serum levels on day 9 to 13. We have
previously shown that when taking 160 mg three times a day
serum levels of tamoxifen plateau at around 4 JAM after 10
days while levels ofNDMTx reach 7 AM after 21 days (Stuart
et al., 1991). Levels would therefore be expected to be higher
on day 9 to 13 than on day 4, as in the present study. Timing
of serum samples in relation to peak levels may be important
as may differences in methodology - Trump et al. give no
details of their methodology. Their report is however, consis-
tent with the results of the present study and supports the
non-linear pharmacokinetics of tamoxifen.
The in vitro studies reported here show that neither
tamoxifen nor verapamil has a major effect on etoposide
cytotoxicity in the cell lines assessed. Tamoxifen produced a
statistically significant enhancement of etoposide cytotoxicity
in the MCF-7 wt cell line and had the opposite effect in the
MCF-7 adr4 line while verapamil produced similar effects.
These changes were, however, modest in extent (maximum
enhancement 1.9-fold) and too small to be of any clinical
significance. Previous reports have shown that tamoxifen can
reverse drug resistance in a number of in vitro models but
these have mainly assessed adriamycin cytotoxicity. Our
group has reported that tamoxifen enhances dox cytotoxicity
in the MCF-7 adrr cell line and has similar effects on vinblas-
tine cytotoxicity in the S1/1.1 and CHO-KI adrr (Kirk et al.,
1991 #117; Kirk, 1992; in press). Ramu et al. initially
assessed the effects of a range of triparanol compounds,
including tamoxifen, on adriamycin cytotoxicity towards the
P388 murine leukaemia line and its adriamycin resistant sub-
line (P388/ADR) (Ramu et al., 1984). They showed that 3 JAM
tamoxifen partially reversed the resistance of the P388/ADR
line. Foster et al. assessed both adriamycin and vinblastine
cytotoxicity in the MCF-7 adrr cell line used in the present
study and also showed partial reversal in the presence of
10 gM tamoxifen (Foster et al., 1988). The effect of tamoxifen
on dox cytotoxicity towards the CHO-KI and CHO-KI adrr
cell lines has also been assessed by Chatterjee and Harris
who have shown enhancement of cytotoxicity in both the
parental (4.8-fold) and dox resistant lines (16-fold) (Chatter-
jee et al., 1990b). Other reports confirm the resistance
modifying effects of tamoxifen (Berman et al., 1991) but none
have assessed its effects on etoposide cytotoxicity.
The mechanism whereby tamoxifen modified dox and vin-
blastine cytotoxicity is not known. Tamoxifen does not
appear to bind to Pgp (Kessel, 1986) but it does inhibit both
calmodulin (Tsuruo et al., 1983) and protein kinase C (Hor-
gan et al., 1986). Both enzymes have been suggested as
possible mechanisms by which drug resistance could be
modified. PKC phosphorylates and activates Pgp (Chambers
et al., 1990) while inhibition of PKC downregulates Pgp
function and enhances drug cytotoxicity (Ma et al., 1991).
Other mechanisms independent ofPgP, by which cytotoxicity
could be modulated, have also been suggested (Baas et al.,
1990; Hindenburg et al., 1987).
Many other drugs have been reported to modify multidrug
resistance and verapamil is perhaps the most studied of these
(Ford et al., 1990). These studies have concentrated on
enhancement of vinblastine and dox cytotoxicity but some
have assessed multidrug resistance in more detail. Merry et
al. have used an in vivo model and have developed a drug
resistant variant of the Ridgway osteogenic sarcoma (Merry
et al., 1991). This showed moderate resistant to actinomycin-
D (1.5 fold), vincristine (3.5-fold) and etoposide (5-fold). In
this case verapamil was equally effective in reversing the
resistance to each agent. Other work using Chinese hamster
lung (DC3F/ADX) and breast cancer (MCF-7 adrr) cell lines
has shown that, while verapamil effectively reverses resistance
to vincristine in multidrug resistant mutants (11-125 fold
enhancement), it has only modest effects on etoposide resis-
tance (3-4 fold) (Politi et al., 1990). Politi et al. also showed
that verapamil had little effect on intracellular etoposide
accumulation and that etoposide had lower affinity for Pgp
than vincristine. Beck et al. have also assessed the ability of
verapamil to overcome multidrug resistance in a human leuk-
aemic cell line (CEM/VBL100) and have confirmed a modify-
ing effect on the cytotoxicity of vinca alkaloids (Beck et al.,
1986). In this case other drugs (including doxorubicin and
etoposide) were unaffected. It therefore appears that reversal
of multidrug resistance is not an 'all or none' effect and
various elements of the multidrug resistant phenotype can be
differentially affected.
Although Pgp expression alone is sufficient for the deve-
lopment of the MDR phenotype (Lincke et al., 1990), it is
known that many other mechanisms exist. The observation
that resistance modifiers known to act on Pgp only partially
reverse drug resistance in Pgp expressing cell lines (Politi et
al., 1989) points to the presence of additional resistance
mechanisms in these cell lines. Where Pgp plays only a minor
role, altering its function may show little effect on overall
levels of resistance. Lincke et al. report that transfection of
the mdrl gene into chemosensitive human BRO melanoma
cells produces a typical MDR phenotype which can be par-
tially reversed with verapamil (Lincke et al., 1990). The S1
parental cell line used in the present study was transfected
with the same gene but has much higher inherent resitance
than the parental BRO cell line (IC50 for etoposide; S1 =
3JAM, BRO = 0.016gM). In the S1/1.1 cell line other resis-
tance mechanisms are likely to be present explaining the lack
of effect of verapamil. Certain of these mechanisms may
themselves be potential targets for modification. Changes in
topoisomerase II, in site of activity of etoposide, may
account for certain patterns of drug resistance. Low levels of
topoisomerase expression have been related to etoposide
(Kim et al., 1992) as well as to drugs with other sites of
action (Giaccone et al., 1992). Phosphorylation of topoiso-
merase II can also enhance resistance to etoposide (Devore et
al., 1992) and would be a potential route of modulation of
drug resistance.
The clinical study reported here shows that tamoxifen at a
dose of either 480 mgday-' or 720 mgday-' can achieve, by
the 4th day, serum levels of tamoxifen sufficient to modulate
drug resistance in other in vitro models. When given for up
to 6 days such doses produce acceptable toxicity. The value
of tamoxifen as an in vivo modulator of drug resistance
therefore deserves further study. For clinical studies we
recommend intermittent high-doses of tamoxifen (480 mg
day-') combined with cytotoxic drugs whose toxicity is
significantly modulated in vitro. Compounds related to tamo-838 N.S.A. STUART et al.
xifen such as toremifene also need to be assessed in this
context. Toremifene can be administered at higher doses than
tamoxifen (Kohler et al., 1990; Robinson et al., 1990) and
higher serum levels can be achieved (DeGregorio et al., 1989;
Kaye, 1990). It is also an effective enhancer of drug toxicity
in MDR-positive cell lines (Kirk, 1992; in press).
The in vitro data show that, although etoposide resistance
is an accepted part of the MDR phenotype, this resistance is
not affected by tamoxifen or verapamil which are effective
modulators of the cytotoxicity of other drugs that are part of
the MDR phenotype. Other studies however, show that novel
modulators such as cyclosporin analogues may have a much
greater effect on etoposide cytotoxicity (Gaveriaux et al.,
1991). Future clinical studies using modifiers of multidrug
resistance need to select cytotoxic drugs that have been
shown to be modulated in vitro by the modifier being
assessed. The combination of etoposide and tamoxifen is a
poor candidate for such studies.
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